|Description||Enrasentan, an indene derivative, has been found to be an endothelin receptor antagonist that was once studied in reperfusion injury and heart failure therapy.|
|Synonyms||Enrasentan; SB-217242; UNII-QG16H8A6ZH; SB 217242; SB217242; CHEMBL431651; (1S,2R,3S)-1-(1,3-benzodioxol-5-yl)-3-[2-(2-hydroxyethoxy)-4-methoxyphenyl]-5-propoxy-2,3-dihydro-1H-indene-2-carboxylic acid|
|Storage||Store in a cool and dry place and at 0 - 4 °C for short term (days to weeks) or -20 °C for long term (months to years).|
|Quality Standard||In-house standard|
N-Despropyl-macitentan, an active metabolite of Macitentan, is a dual ET receptor antagonist with longer half-life than Macitentan. It has been proved to be eff...
Darusentan is a selective endothelin-1 receptor A inhibitor. Darusentan is identified as the treatment of congestive heart failure, hypertension and cancers. It...
IRL-2500, an indol derivative, has been found to be an endothelin B receptor antagonist that was once studied in hypertension.
Clazosentan, also called as AXV 034, Ro 61-1790 or VML 588, a novel endothelin A antagonist, improves cerebral blood flow and behavior after traumatic brain inj...
Edonentan, also known as BMS-207940, is a very potent and selective ETA endothelin receptor antagonist (Ki= 10 pM) that shows 80000-fold selective for ETA vs ET...
CI 1020 has been found to be a novel endothelin-A receptor antagonist and could be used as an antihypertensive agent.
Zibotentan is an orally administered, potent and specific ETA-receptor (endothelin A receptor) antagonist (IC50 = 21 nM).
FR 139317 is a selective Endothelin A receptor antagonist originated by Fujisawa. (Ki values are 1 nM and 7.3 μM at ETA and ETB subtypes respectively). No devel...